Standard BioTools' (LAB) shares were down about 9% in recent Thursday trading after KeyBanc downgraded the company's stock to sector weight from overweight.
The downgrade followed the company's "disappointing" full year 2025 guidance, Keybanc said in an earnings recap Wednesday.
The firm said Standard BioTools' 2025 revenue outlook of $165 million to $175 million fell short of the $186.9 million consensus estimate and KeyBanc's $185 million projection.
"The company attributed its guidance to the proposed White House [National Institutes of Health] spending cut that may drive cautious spending for its academic customers," KeyBanc said.
Trading volume stood at more than 3.6 million shares against a daily average of roughly 1.7 million.
Price: 1.07, Change: -0.11, Percent Change: -8.97
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.